Travaux scientifiques

Doç. Dr. Erkan Kayıkçıoğlu

54 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil

  1. In Regard to Peltenburg et al

    Practical Radiation Oncology, 2026

    DOI 10.1016/j.prro.2026.01.020 PMID 42971673 Source : OpenAlex

  2. Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

    Clinical Breast Cancer, 2025

    DOI 10.1016/j.clbc.2025.03.003 PMID 40190010 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  3. HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy

    Turkish Journal of Clinics and Laboratory, 2025

    DOI 10.18663/tjcl.1639022 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  4. The Gustave Roussy immune score as a novel biomarker for predicting survival in patients with isocitrate dehydrogenase wild-type glioblastoma treated with the Stupp protocol

    Expert Review of Anticancer Therapy, 2025

    DOI 10.1080/14737140.2025.2555467 PMID 40883857 1 citation (Europe PMC) Source : OpenAlex

  5. Refining risk stratification in PSMA-PET guided salvage radiotherapy: methodological and translational considerations

    Radiotherapy and Oncology, 2025

    DOI 10.1016/j.radonc.2025.111234 PMID 41171646 Source : OpenAlex

  6. Minimally Invasive Surgery Versus SABR in Stage IA NSCLC: Interpreting Real-World Evidence with Caution

    Clinical Lung Cancer, 2025

    DOI 10.1016/j.cllc.2025.11.002 PMID 41314019 Source : OpenAlex

  7. Beyond BMI: Metabolic and Inflammatory Determinants of Recurrence After Neoadjuvant Therapy in Breast Cancer

    Clinical Breast Cancer, 2025

    DOI 10.1016/j.clbc.2025.11.004 PMID 41319354 Source : OpenAlex

  8. Subcutaneous pertuzumab–trastuzumab: Efficiency, safety, and the biosimilar horizon

    The Breast, 2025

    DOI 10.1016/j.breast.2025.104651 PMID 41274854 Texte intégral en libre accèsSource : OpenAlex

  9. Machine learning for predicting colon cancer recurrence

    Surgical Oncology, 2024

    DOI 10.1016/j.suronc.2024.102079 PMID 38688191 9 citations (Europe PMC) Source : OpenAlex

  10. Assessment of polypharmacy, potentially inappropriate medications, and drug-drug interactions in older patients with cancer

    Journal of Oncology Pharmacy Practice, 2024

    DOI 10.1177/10781552241255140 PMID 38751371 5 citations (Europe PMC) Source : OpenAlex

  11. Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study

    Journal of Chemotherapy, 2024

    DOI 10.1080/1120009x.2024.2330835 PMID 38497444 7 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  12. Pan-Immune-Inflammation Value as a Novel Prognostic Biomarker for Advanced Pancreatic Cancer

    Cureus, 2024

    DOI 10.7759/cureus.71251 PMID 39525139 9 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  13. The Prognostic Significance of CD47, CD68, and CD163 Expression Levels and Their Relationship with MLR and MAR in Locally Advanced and Oligometastatic Nasopharyngeal Carcinoma

    Diagnostics, 2024

    DOI 10.3390/diagnostics14232648 PMID 39682556 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  14. Challenging VIPoma Case Treated with Sunitinib: A Life-Saving Therapeutic Experience

    Journal of Oncological Sciences, 2024

    DOI 10.37047/jos.2024-105122 Source : OpenAlex

  15. Kanser hastalarında sosyodemografik faktörler, klinik özellikler ve anksiyete düzeyleri arasındaki ilişki: Kesitsel bir çalışma

    Turkish Journal of Clinics and Laboratory, 2024

    DOI 10.18663/tjcl.1464946 Source : OpenAlex

  16. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

    BMC Cancer, 2023

    DOI 10.1186/s12885-023-10609-8 PMID 36765293 18 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  17. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

    Future Oncology, 2023

    DOI 10.2217/fon-2022-1287 PMID 37133230 22 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  18. Prognostic value of claudin 18.2 expression in gastric adenocarcinoma

    World Journal of Gastrointestinal Oncology, 2023

    DOI 10.4251/wjgo.v15.i2.343 PMID 36908327 24 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  19. The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes

    Medicine, 2023

    DOI 10.1097/md.0000000000032882 PMID 36820561 15 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  20. A Novel Prognostic Index for Metastatic Colon Cancer: The Prognostic Immune Nutritional Index

    Cureus, 2023

    DOI 10.7759/cureus.33808 PMID 36819360 7 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  21. Potential drug–drug interactions in patients with non-small cell lung cancer at a university hospital in Turkey

    Journal of Cancer Research and Clinical Oncology, 2023

    DOI 10.1007/s00432-023-04890-0 PMID 37222813 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  22. Prognostic value of computed tomography associated body composition measurement changes in metastatic colorectal cancer patients

    Acta Radiologica, 2023

    DOI 10.1177/02841851231198345 PMID 37661639 2 citations (Europe PMC) Source : OpenAlex

  23. The Efficacy of Pazopanib in Ewing Sarcoma

    Zenodo (CERN European Organization for Nuclear Research), 2023

    DOI 10.5281/zenodo.7709542 Source : OpenAlex

  24. Ewing Sarkomunda Pazopanib’in Etkinliği: Ewing Sarkomunda Pazopanib

    Chronicles of Precision Medical Researchers, 2023

    Source : OpenAlex

  25. The Pan-Immune-Inflammation Value Predicts the Survival of Patients with ER-positive, HER-2-Negative Metastatic Breast Cancer Treated with CDK4/6 inhibitors

    Zenodo (CERN European Organization for Nuclear Research), 2022

    DOI 10.5281/zenodo.7195779 Source : OpenAlex

  26. Prognostic value of clinicopathological characteristic of patients with Malign Mesothelioma at Mediternean region of Turkey

    Journal of Contemporary Medicine, 2022

    DOI 10.16899/jcm.1173730 Source : OpenAlex

  27. Pan-Immun-Inflammation-Değeri’nin CDK4/6 inhibitörleri ile Tedavi Edilen Östrojen Reseptörü-Pozitif,İnsan Epidermal Büyüme Faktörü 2 (HER2)-Negatif Metastatik Meme Kanseri Hastalarında Sağkalımı Öngörür : CDK4/6 inhibitörleri ile Tedavi Edilen Metastatik Meme Kanseri Meme Kanserinde Pan-İmmün-İnflamasyon-Değeri

    Chronicles of Precision Medical Researchers, 2022

    Source : OpenAlex

  28. Acute pancreatitis linked to bevacizumab: A case report

    Journal of Oncological Sciences, 2018

    DOI 10.1016/j.jons.2018.03.004 Source : OpenAlex

  29. A challenging palliation via novel therapeutic approach for unusual presenting with gingival metastasis from renal cell carcinoma relapsed eight years after nephrectomy

    The European Research Journal, 2018

    DOI 10.18621/eurj.348318 Source : OpenAlex

  30. An extremely rare neoplasm, histiocytic sarcoma: A report of two cases with an aggressive clinical course

    Journal of Oncological Sciences, 2017

    DOI 10.1016/j.jons.2017.05.007 Source : OpenAlex

  31. Selçuk Üniversitesi Meram Tıp Fakültesi sağlık çalışanlarında fonksiyonel gastrointestinal bozuklukların Roma III Kriterleri eşliğinde sıklığı ve birlikteliğinin belirlenmesi

    2010

    Source : OpenAlex

  32. A Comparison of Maternal and Fetal Outcomes of Pregnancies Complicated by Moderate to Severe Thrombocytopenia Caused by Gestational Thrombocytopenia Preeclampsia / HELLP Syndrome and Immune Thrombocytopenic Purpura

    DOAJ (DOAJ: Directory of Open Access Journals), 2008

    Source : OpenAlex

  33. KAYIKÇIOĞLU ERKAN (2022). Isparta Burdur Yöresindeki Kolon Kanseri Hastalarının Demografik ve Klinik Özellikleri. Medical Journal of Suleyman Demirel University, 29(3), 386- 389., Doi: 10.17343/sdutfd.1104209

    Source : page de profil sur livhospital.com

  34. ÜNER SARP, VAİZOĞLU SONGÜL ACAR, ALP SERAP AYNUR, SİMAVLI HÜSEYİN, MAUNSOUR NAİM, EL- HATOU HASSAN, NEPREVİSTA ERVİN, KAYIKÇIOĞLU ERKAN, GÜLER ÇAĞATAY (2007). Lise Öğrencilerinin Tüketici Hakları Konusunda Bilgi Ve Tutumlarının Değerlendirmesi. TOPLUM HEKİMLİĞİ BÜLTENİ, 26(2), 16-21

    Source : page de profil sur livhospital.com

  35. KAYIKÇIOĞLU ERKAN, FİNDOS EDA (2022). The prognostic immune nutritional index is a predictive biomarker in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide. The Injector, 1(3), 106-114., Doi: 10.5281/zenodo.7331456

    Source : page de profil sur livhospital.com

  36. Aydın Asım Armagan, Cetin Furkan Bertug, KAYIKÇIOĞLU ERKAN, Ozturk Banu, Yildiz Mustafa (2017). A unique case of malignant pleural mesothelioma presenting with highly aggressive multiple brain metastases after a long disease-free period. Cumhuriyet Medical Journal, 39(3), 624-628., Doi: 10.7197/223.v39i31705.347463

    Source : page de profil sur livhospital.com

  37. Aydın Asım Armagan, GÜNDÜZ UMUT RIZA, YALÇINKAYA SONER, KAYIKÇIOĞLU ERKAN, Alparslan Ahmet Şükrü, Yaz Mujgan, Ozturk Banu (2016). A Rare Case of Primary Breast Cancer with Isolated Renal Parenchymal Metastasis Mimicking Primary Renal Cell Carcinoma. Journal of Clinical Case Reports, 6(2), Doi: 10.4172/2165-7920.1000724

    Source : page de profil sur livhospital.com

  38. ATALAY HÜSEYİN, Güney İbrahim, Bağlıcakoğlu Murat, KAYIKÇIOĞLU ERKAN, TONBUL HALİL ZEKİ (2008). Sürekli Ayaktan Periton Diyalizi Uygulanmakta Olan Bir Hastada Stenotrophomonas maltophilia Peritoniti. Turkish Journal of Nephrology, 17(3), 124-125.

    Source : page de profil sur livhospital.com

  39. ÖZDEMİR SUNA, GÖRKEMLİ HÜSEYİN, ACAR Ali, KAYIKÇIOĞLU ERKAN (2008). Idarubicine Treatment of Acute Myeloblastic Leukemia During Pregnancy: Case Report. Turkiye Klinikleri Journal of Gynecology and Obstetrics, 18, 145-148.

    Source : page de profil sur livhospital.com

  40. COVID 19 ENFEKSİYONU SONRASI MYASTENIA GRAVIS VE TEDAVİ YANITI GÖRÜLEN PLEVRAL TİMOMA OLGUSU , KAYIKÇIOĞLU ERKAN, AYYILDIZ VEYSEL ATİLLA, EVRİMLER ŞEHNAZ, DÖNGEL İSA, ÇETİN BÜLENT (2021).. 5.ULUSAL İMMUNOTERAPİ VE ONKOLOJİ KONGRESİ, (Özet bildiri) B-751-8986

    Source : page de profil sur livhospital.com

  41. Nadir bir antite: Mandibular Kemiğin Dev Hücreli Tümörü , KAYIKÇIOĞLU ERKAN, Çetin Bülent (2021).. 5.ULUSAL İMMÜNOTERAPİ VE ONKOLOJİ KONGRESİ, (Özet bildiri) B-820-1188

    Source : page de profil sur livhospital.com

  42. Süleyman Demirel Üniversitesi Tıp Fakültesi Tıbbi Onkoloji Ünitesinde C-Erb B2 (Her2) Pozitif Trastuzumab Tabanlı Tedavi Gören Meme Kanseri Hastalarında Wbp2 Ekspresyonunun Prognostik Önemi , OLGUN NURULLAH VOLKAN, KAYIKÇIOĞLU ERKAN, BOZKURT KEMAL KÜRŞAT, BACAK BURCU, GÜMÜŞAY ÖZGE, ÇETİN BÜLENT (2021) 5.ULUSAL İMMÜNOTERAPİ VE ONKOLOJİ KONGRESİ

    Source : page de profil sur livhospital.com

  43. Covid 19 Enfeksiyonu Sonrası Myastenia Gravis ve Tedavi Yanıtı Görülen Plevral Timoma Olgusu , KAYIKÇIOĞLU ERKAN, AYYILDIZ VEYSEL ATİLLA, EVRİMLER ŞEHNAZ, DÖNGEL İSA, Çetin Bülent (2021).. 5.ULUSAL İMMÜNOTERAPİ VE ONKOLOJİ KONGRESİ, (Özet bildiri)

    Source : page de profil sur livhospital.com

  44. THE SIGNIFICANCE OF THE PREOPERATIVE FDG PET - CT SUV MAX VALUE ON DISEASE RECURRENCE IN OPERATED NSCLC PATIENTS , KARAMAN ELANUR, KAYIKÇIOĞLU ERKAN (2019).. 3.ULUSAL İMMÜNOTERAPİ VE ONKOLOJİ KONGRESİ, 3(1), (Özet bildiri)

    Source : page de profil sur livhospital.com

  45. PSYCHOLOGICAL SYMPTOMS, DEATH ANXIETY AND ANGER IN ELDERLY PATIENS WITH CANCER , KAYIKÇIOĞLU ERKAN, BACIK YAMAN GÖZDE (2023).. 6 Health Sciences and Life Congress,

    Source : page de profil sur livhospital.com

  46. KANSER HASTASI YAKINI KADINLARDA SERVİKS KANSERİ RİSK FAKTÖRLERİ VE TARAMA YÖNTEMLERİ FARKINDALIĞI , KAYIKÇIOĞLU ERKAN (2023).. INTERNATIONAL EUROASIA

    Source : page de profil sur livhospital.com

  47. COLON CANCER AWARENESS AMONG MALE RELATIVES OF CANCER PATIENTS , KAYIKÇIOĞLU ERKAN (2023).. 10. INTERNATIONAL GEVHER NESİBE MEDICAL SCIENCES CONFERENCE

    Source : page de profil sur livhospital.com

  48. THE RELATIONSHIP BETWEEN PERCEİVED STRESS, EMOTİON REGULATİON, AND ATTACHMENT STYLES İN CANCER PATİENTS , BACIK YAMAN GÖZDE, KAYIKÇIOĞLU ERKAN (2022).. 4. INTERNATIONAL SCIENTIFIC RESEARCH AND INNOVATION CONGRESS

    Source : page de profil sur livhospital.com

  49. MEME KANSERİ HORMON RESEPTÖRÜ POZİTİF HER2 NEGATİF ALTGRUBUNDA GÜNCEL TEDAVİ YAKLAŞIMLARI , KAYIKÇIOĞLU ERKAN (2022).. 1 st INTERNATIONAL – 4 th NATIONAL HEALTH SERVICES CONGRESS

    Source : page de profil sur livhospital.com

  50. Hereditary Gynecological Cancers and the Role of Molecular Pathology in Prognosis and Treatment, Bölüm adı:(DNA Hasarı Tamir Mekanizmalarını Hedef Alan Gelişmekte Olan Ajanlar) (2022)., KAYIKÇIOĞLU ERKAN, ÇETİN BÜLENT, Turkiye Klinikleri Gynecology Obstetrics - Special Topics Book Identity, Editör:ÜNAL ORHAN, Basım sayısı:1, Sayfa Sayısı 102, ISBN:978-625-401-840-4, Türkçe

    Source : page de profil sur livhospital.com